Population
Type 3 poliovirus (antigenic mutants)
Design
Preclinical
Authors
Loading...
May inform type 3 poliovirus vaccine design; leaves open human validation and clinical translation.
Identified a specific eight-amino acid region in the VP1 protein as a major target for type 3 poliovirus neutralization, which is likely necessary for vaccine development.
Minor et al. (1984) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: